Kyverna Therapeutics Announces $100 Million Public Offering

An announcement from Kyverna Therapeutics, Inc. ( (KYTX) ) is now available.

On December 17, 2025, Kyverna Therapeutics, Inc. priced an underwritten public offering of 13,333,333 shares of common stock at $7.50 per share, for expected gross proceeds of approximately $100 million, with a 30-day option granted to underwriters to purchase up to an additional 1,999,999 shares; the deal, conducted off an effective Form S-3 shelf registration, is expected to close on or about December 18, 2025, subject to customary conditions. The transaction, for which all shares are being sold by the company and major shareholders are bound by lock-up agreements through January 31, 2026, will provide Kyverna with fresh capital for general corporate purposes including research and development, capital expenditures, and working capital, reinforcing its funding base as it advances its CAR T-cell programs and registrational trials in autoimmune indications.

The most recent analyst rating on (KYTX) stock is a Buy with a $33.00 price target. To see the full list of analyst forecasts on Kyverna Therapeutics, Inc. stock, see the KYTX Stock Forecast page.

Spark’s Take on KYTX Stock

According to Spark, TipRanks’ AI Analyst, KYTX is a Underperform.

Kyverna Therapeutics, Inc. faces significant financial challenges, with consistent losses and zero revenue. The company’s technical indicators and valuation metrics reflect ongoing operational and financial difficulties. Key risks include negative profitability and weak market momentum, which significantly impact the stock’s performance.

To see Spark’s full report on KYTX stock, click here.

More about Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases. Its lead product candidate is miv-cel (mivocabtagene autoleucel, KYV-101), an autologous CD19-targeting CAR T-cell therapy, and it is building a potentially first-in-class neuroimmunology franchise, including a recently completed registrational trial in stiff person syndrome and an ongoing registrational trial in generalized myasthenia gravis, alongside additional KYSA and investigator-initiated trials in multiple sclerosis and rheumatoid arthritis and a next-generation CAR T pipeline aimed at improving patient access and experience.

Average Trading Volume: 1,272,554

Technical Sentiment Signal: Strong Buy

Current Market Cap: $448.5M

Learn more about KYTX stock on TipRanks’ Stock Analysis page.